Immuno-Safety Technical Committee (ITC)

Mission Statement

The mission of the HESI Immuno-Safety Technical Committee (ITC) is to identify and address scientific issues related to immune safety and translation to human health risk assessment.

Key Objectives:

  • Leverage technical and scientific expertise from academic, regulatory, and industry organizations to advance immuno-safety science
  • Contribute to the scientific decision-making processes relative to the development of guidelines and regulations for immune safety testing
  • Educate stakeholders in safety science and promote the understanding and appropriate use of immune safety data

Regulatory Strategies and Risk Assessment Workstreams

  • 3Rs and Alternative Models for Biologics

    This workstream explores the use of New Approach Methodologies (NAMs), including in vitro and in silico tools, as alternatives to animal testing for biologics. As regulatory acceptance of NAMs continues to evolve, the team is identifying scenarios where these approaches are scientifically valid and regulatory-compliant. Deliverables include generation of case studies, identification of key data gaps, and development of strategies to build regulatory confidence in NAM-based immune safety assessments. The ultimate goal is to support more ethical, efficient, and science-based approaches to evaluating biologics.

    Working Group: Regulatory Strategies and Risk Assessment

  • Translatability of Non-Relevant Immunotoxic Findings

    This project addresses challenges in interpreting nonclinical immunotoxicity findings that are specific to a species or model system. These findings are often mischaracterized as human-relevant, leading to unnecessary delays or conservative risk management decisions. The workstream is focused on generating practical strategies to contextualize such findings using mechanistic understanding, case studies, and emerging tools like NAMs. The goal is to improve the consistency and scientific validity of regulatory assessments by distinguishing between isolated model artifacts and true indicators of human risk.

    Working Group: Regulatory Strategies and Risk Assessment

  • Carcinogenicity Weight of Evidence (WOE)

    This workstream is developing a weight-of-evidence approach to evaluate the carcinogenic potential of immunomodulatory compounds. It aims to integrate data sourcesā€”including clinical label information, mechanistic insights, and CRA dataā€”to inform hazard identification. The framework will support decisions about when additional testing (e.g., carcinogenicity studies) may or may not be needed. (Already listed on the site.)

  • Best Practices for Cytokine Release Assays (CRA)

    The team is creating a practical, science-based decision tree to guide the appropriate use of cytokine release assays (CRAs) in preclinical hazard identification. This tool will help determine when CRAs are warranted based on therapeutic modality, mechanism of action, and risk context. The group is also compiling real-world case studies to illustrate best practices and limitations, aiming to foster more consistent application and interpretation of CRAs across the field.

Translational Immunosafety Workstreams

  • Translating Nonclinical to Clinical Outcomes ā€“ A Retrospective Analysis

    This workstream is undertaking a retrospective analysis of preclinical immune safety data to determine its predictive value for human clinical outcomes. The project will identify correlations and disconnects between observed nonclinical findings and clinical manifestations, helping to refine how preclinical immune effects are interpreted. The team aims to produce guidance and models to support translational decision-making and risk assessment for new therapies.

  • Translational Relevance of NHP Immunotoxicities

    The goal of this workstream is to evaluate the translational relevance of immunotoxic findings observed in non-human primates (NHPs), particularly cynomolgus monkeys. Using age-stratified models and comparative data analyses, the team will assess when NHP data are informative of human risk and when alternative models may be preferable. A weight-of-evidence (WOE) framework will be developed to guide selection of the most appropriate models for specific immuno-safety questions. This will support regulatory alignment and refinement of species selection practices.

  • Comparative Immune Biology

    This project supports species selection for biologics safety assessment by examining immune system similarities and differences across species. Key activities include: (1) development of a decision tree with critical considerations for species choice, including alternatives to NHPs; (2) assessment of reagent availability and operational feasibility for non-traditional models; (3) promotion of novel study designs and humanized models to improve predictive accuracy; and (4) publication of a white paper synthesizing findings and offering best practice recommendations to guide immunotoxicology studies.

  • FIH Dose commentary

    This expanded commentary on the recently published Ā FIH Dose Selection Beyond MABEL: – continues discussions on optimizing Phase 1 clinical trial starting dose while protecting patient safety. Submission planned to Regulatory Toxicology & Pharmacology this spring. Group to sunset after publication.

  • CRA in Cynomolgus Monkeys

    This manuscript-based project focuses on differentiating true test article-related cytokine changes from natural baseline variability in cynomolgus monkeys. Drawing on retrospective data and industry experience, the team has identified key trends and messages to inform CRA interpretation. Most manuscript sections are complete, and final polishing and figure edits are underway. The findings will support improved use of CRAs in NHP models and enhance interpretation in regulatory contexts.

  • Clinician Roundtable

    This ad hoc group is composed of clinical, regulatory, and scientific experts and is reactivated as needed to provide input on emerging translational challenges. It serves as a bridge between nonclinical findings and real-world clinical application, offering strategic insight that can guide ongoing workstreams or initiate new ones based on relevance to patient safety and therapeutic outcomes.

Methods development Workstreams

  • NAMs/CIVMs (Complex In Vitro Models)

    This workstream is assessing the utility of complex in vitro models (CIVMs), including organ-on-chip systems, 3D cultures, and immune-competent models, in immune safety evaluations. These models represent a promising alternative to animal studies and may enhance human relevance. The project will evaluate the current state of CIVMs, identify performance gaps, and provide guidance on effective implementation, validation considerations, and best practices to support regulatory confidence and adoption.

  • Immunogenicity

    This project focuses on improving the reliability and standardization of immunogenicity risk assessment methods. Key activities include: (1) development of shared reagents (e.g., lyophilized monoclonal antibodies with well-characterized ADA profiles) to improve reproducibility of in vitro T-cell and innate immune assays; (2) comparative analysis of empirical methods with in silico prediction tools to define complementary strengths and limitations; and (3) collaboration with groups like AAPS to develop best practices and fit-for-purpose tools. The goal is to create a comprehensive, integrated framework for identifying and managing immunogenicity risk.

  • Evaluating NK Function Assays

    This workstream supports the development and standardization of natural killer (NK) cell functional assays used in immune safety evaluations. It aims to address challenges in assay variability, reagent selection, and interpretation. The group is working toward aligning methodologies that can be confidently applied across diverse therapeutic platforms.

Education & Outreach Workstreams

  • Background

    This cross-functional initiative aims to enhance the visibility and impact of ITC science. Key efforts include: (1) proactive engagement with professional societies through sessions, working groups, and presentations; and (2) broad dissemination of ITC-generated knowledge via open access publications, social media campaigns, webinars, podcasts, and other communication channels. The goal is to expand awareness of immuno-safety science, drive participation, and foster collaboration across sectors.

  • Immuno safety course

    This on-demand educational course is designed to support continuing education for scientists, regulators, and stakeholders working in immunotoxicology. Developed and delivered by ITC experts, the course covers key tools, concepts, and case examples relevant to immune safety evaluation. It is intended to strengthen scientific literacy and promote consistent application of immuno-safety principles across programs.

  • Immunosafety Manuscript

    This manuscript, targeted for publication in the Journal of Immunology (AAI), provides a concise overview of the emerging field of immuno-safety science and its relevance at the intersection of basic and translational immunology. The piece advocates for the early and proactive integration of immune safety principles into immunology education, research design, and therapeutic development. The goal is to raise awareness within the broader immunology community and foster greater alignment between discovery science and safe clinical application.

Committee Resources

Mentorship Program

The HESI ITC seeks graduate students working in immunology, toxicology, pathology, or related field for a second cycle of their new HESI ITC Mentorship Program. This program will allow meaningful interactions between trainees and mentors to give insight on various career pathways and discuss how to streamline the menteesā€™ long-term goals. The second cohort will tentatively be from May ā€“ June 2023 with 4-5 one-on-one mentor meetings. As well as an opportunity to network with past mentees and expert immuno-safety committee members at our ITC annual meeting (25-26 April 2023).

  • Qualifications and Requirements: Eligible candidates must be currently enrolled in a graduate program (MS or PhD candidates) in immunology, toxicology, pathology or related field (cell biology, biochemistry, biomedical engineering, or similar). And must have completed at least one year in their program.
  • Submission window is now closed

If you have any questions about the HESI ITC or this program, please contact Dr. Shermaine Mitchell-Ryan

Congratulations to the 2023 Professional Development Awardees!

1. Ishita Choudhary, Louisiana State University
Research area: Investigating the mechanisms of ozone and allergen induce lung injury.

2. Jaclynn Meshanni, Rutgers University
Research area: The role of Lipid homeostasis in macrophages and its impact on the development of Pulmonary fibrosis resulting from Nitrogen mustard exposure.

HESI Staff

Leadership Team

  • Marc Pallardy, PhD

    UniversitƩ Paris-Saclay

  • HervĆ© Lebrec, PhD

    Amgen, Inc.

  • Curtis Maier, PhD

    GlaxoSmithKline

Committee Events

Filter

No results.

WP_Query Object
(
    [query] => Array
        (
            [post_type] => event
            [posts_per_page] => 6
            [type] => 
            [area] => 
            [before] => 2050-01-01
            [after] => 
            [tags] => ITC
            [showtitle] => false
            [meta_query] => Array
                (
                    [relation] => AND
                    [0] => Array
                        (
                            [key] => _ilsi_date
                            [value] => 2050-01-01
                            [compare] => <=
                        )

                    [1] => Array
                        (
                            [key] => _ilsi_end_date
                            [value] => 2050-01-01
                            [compare] => <=
                        )

                    [2] => Array
                        (
                            [key] => _ilsi_date
                            [value] => Array
                                (
                                    [0] => 2025-10-01
                                    [1] => 2025-10-31
                                )

                            [compare] => BETWEEN
                        )

                )

            [paged] => 1
            [tax_query] => Array
                (
                    [0] => Array
                        (
                            [taxonomy] => post_tag
                            [field] => name
                            [terms] => ITC
                        )

                )

            [meta_key] => _ilsi_date
            [orderby] => meta_value
            [order] => ASC
        )

    [query_vars] => Array
        (
            [post_type] => event
            [posts_per_page] => 6
            [type] => 
            [area] => 
            [before] => 2050-01-01
            [after] => 
            [tags] => ITC
            [showtitle] => false
            [meta_query] => Array
                (
                    [relation] => AND
                    [0] => Array
                        (
                            [key] => _ilsi_date
                            [value] => 2050-01-01
                            [compare] => <=
                        )

                    [1] => Array
                        (
                            [key] => _ilsi_end_date
                            [value] => 2050-01-01
                            [compare] => <=
                        )

                    [2] => Array
                        (
                            [key] => _ilsi_date
                            [value] => Array
                                (
                                    [0] => 2025-10-01
                                    [1] => 2025-10-31
                                )

                            [compare] => BETWEEN
                        )

                )

            [paged] => 1
            [tax_query] => Array
                (
                    [0] => Array
                        (
                            [taxonomy] => post_tag
                            [field] => name
                            [terms] => ITC
                        )

                )

            [meta_key] => _ilsi_date
            [orderby] => meta_value
            [order] => ASC
            [error] => 
            [m] => 
            [p] => 0
            [post_parent] => 
            [subpost] => 
            [subpost_id] => 
            [attachment] => 
            [attachment_id] => 0
            [name] => 
            [pagename] => 
            [page_id] => 0
            [second] => 
            [minute] => 
            [hour] => 
            [day] => 0
            [monthnum] => 0
            [year] => 0
            [w] => 0
            [category_name] => 
            [tag] => 
            [cat] => 
            [tag_id] => 814
            [author] => 
            [author_name] => 
            [feed] => 
            [tb] => 
            [meta_value] => 
            [preview] => 
            [s] => 
            [sentence] => 
            [title] => 
            [fields] => all
            [menu_order] => 
            [embed] => 
            [category__in] => Array
                (
                )

            [category__not_in] => Array
                (
                )

            [category__and] => Array
                (
                )

            [post__in] => Array
                (
                )

            [post__not_in] => Array
                (
                )

            [post_name__in] => Array
                (
                )

            [tag__in] => Array
                (
                )

            [tag__not_in] => Array
                (
                )

            [tag__and] => Array
                (
                )

            [tag_slug__in] => Array
                (
                )

            [tag_slug__and] => Array
                (
                )

            [post_parent__in] => Array
                (
                )

            [post_parent__not_in] => Array
                (
                )

            [author__in] => Array
                (
                )

            [author__not_in] => Array
                (
                )

            [search_columns] => Array
                (
                )

            [ignore_sticky_posts] => 
            [suppress_filters] => 
            [cache_results] => 1
            [update_post_term_cache] => 1
            [update_menu_item_cache] => 
            [lazy_load_term_meta] => 1
            [update_post_meta_cache] => 1
            [nopaging] => 
            [comments_per_page] => 50
            [no_found_rows] => 
        )

    [tax_query] => WP_Tax_Query Object
        (
            [queries] => Array
                (
                    [0] => Array
                        (
                            [taxonomy] => post_tag
                            [terms] => Array
                                (
                                    [0] => ITC
                                )

                            [field] => name
                            [operator] => IN
                            [include_children] => 1
                        )

                )

            [relation] => AND
            [table_aliases:protected] => Array
                (
                    [0] => wp_term_relationships
                )

            [queried_terms] => Array
                (
                    [post_tag] => Array
                        (
                            [terms] => Array
                                (
                                    [0] => ITC
                                )

                            [field] => name
                        )

                )

            [primary_table] => wp_posts
            [primary_id_column] => ID
        )

    [meta_query] => WP_Meta_Query Object
        (
            [queries] => Array
                (
                    [0] => Array
                        (
                            [key] => _ilsi_date
                        )

                    [1] => Array
                        (
                            [0] => Array
                                (
                                    [key] => _ilsi_date
                                    [value] => 2050-01-01
                                    [compare] => <=
                                )

                            [1] => Array
                                (
                                    [key] => _ilsi_end_date
                                    [value] => 2050-01-01
                                    [compare] => <=
                                )

                            [2] => Array
                                (
                                    [key] => _ilsi_date
                                    [value] => Array
                                        (
                                            [0] => 2025-10-01
                                            [1] => 2025-10-31
                                        )

                                    [compare] => BETWEEN
                                )

                            [relation] => AND
                        )

                    [relation] => AND
                )

            [relation] => AND
            [meta_table] => wp_postmeta
            [meta_id_column] => post_id
            [primary_table] => wp_posts
            [primary_id_column] => ID
            [table_aliases:protected] => Array
                (
                    [0] => wp_postmeta
                    [1] => mt1
                    [2] => mt2
                    [3] => mt3
                )

            [clauses:protected] => Array
                (
                    [wp_postmeta] => Array
                        (
                            [key] => _ilsi_date
                            [compare] => =
                            [compare_key] => =
                            [alias] => wp_postmeta
                            [cast] => CHAR
                        )

                    [mt1] => Array
                        (
                            [key] => _ilsi_date
                            [value] => 2050-01-01
                            [compare] => <=
                            [compare_key] => =
                            [alias] => mt1
                            [cast] => CHAR
                        )

                    [mt2] => Array
                        (
                            [key] => _ilsi_end_date
                            [value] => 2050-01-01
                            [compare] => <=
                            [compare_key] => =
                            [alias] => mt2
                            [cast] => CHAR
                        )

                    [mt3] => Array
                        (
                            [key] => _ilsi_date
                            [value] => Array
                                (
                                    [0] => 2025-10-01
                                    [1] => 2025-10-31
                                )

                            [compare] => BETWEEN
                            [compare_key] => =
                            [alias] => mt3
                            [cast] => CHAR
                        )

                )

            [has_or_relation:protected] => 
        )

    [date_query] => 
    [request] => SELECT SQL_CALC_FOUND_ROWS  wp_posts.ID
					 FROM wp_posts  LEFT JOIN wp_term_relationships ON (wp_posts.ID = wp_term_relationships.object_id) INNER JOIN wp_postmeta ON ( wp_posts.ID = wp_postmeta.post_id )  INNER JOIN wp_postmeta AS mt1 ON ( wp_posts.ID = mt1.post_id )  INNER JOIN wp_postmeta AS mt2 ON ( wp_posts.ID = mt2.post_id )  INNER JOIN wp_postmeta AS mt3 ON ( wp_posts.ID = mt3.post_id )
					 WHERE 1=1  AND ( 
  wp_term_relationships.term_taxonomy_id IN (814)
) AND ( 
  wp_postmeta.meta_key = '_ilsi_date' 
  AND 
  ( 
    ( mt1.meta_key = '_ilsi_date' AND mt1.meta_value <= '2050-01-01' ) 
    AND 
    ( mt2.meta_key = '_ilsi_end_date' AND mt2.meta_value <= '2050-01-01' ) 
    AND 
    ( mt3.meta_key = '_ilsi_date' AND mt3.meta_value BETWEEN '2025-10-01' AND '2025-10-31' )
  )
) AND ((wp_posts.post_type = 'event' AND (wp_posts.post_status = 'publish' OR wp_posts.post_status = 'acf-disabled')))
					 GROUP BY wp_posts.ID
					 ORDER BY wp_postmeta.meta_value ASC
					 LIMIT 0, 6
    [posts] => Array
        (
        )

    [post_count] => 0
    [current_post] => -1
    [before_loop] => 
    [in_the_loop] => 
    [comment_count] => 0
    [current_comment] => -1
    [found_posts] => 0
    [max_num_pages] => 0
    [max_num_comment_pages] => 0
    [is_single] => 
    [is_preview] => 
    [is_page] => 
    [is_archive] => 1
    [is_date] => 
    [is_year] => 
    [is_month] => 
    [is_day] => 
    [is_time] => 
    [is_author] => 
    [is_category] => 
    [is_tag] => 1
    [is_tax] => 
    [is_search] => 
    [is_feed] => 
    [is_comment_feed] => 
    [is_trackback] => 
    [is_home] => 
    [is_privacy_policy] => 
    [is_404] => 
    [is_embed] => 
    [is_paged] => 
    [is_admin] => 
    [is_attachment] => 
    [is_singular] => 
    [is_robots] => 
    [is_favicon] => 
    [is_posts_page] => 
    [is_post_type_archive] => 
    [query_vars_hash:WP_Query:private] => f5643bd79ac878d70dd3d49c75ebcc07
    [query_vars_changed:WP_Query:private] => 
    [thumbnails_cached] => 
    [allow_query_attachment_by_filename:protected] => 
    [stopwords:WP_Query:private] => 
    [compat_fields:WP_Query:private] => Array
        (
            [0] => query_vars_hash
            [1] => query_vars_changed
        )

    [compat_methods:WP_Query:private] => Array
        (
            [0] => init_query_flags
            [1] => parse_tax_query
        )

    [query_cache_key:WP_Query:private] => wp_query:1c0fd6090e9b426728308fc1882b5d89:0.11611400 17520534210.14463200 1752053421
)

HESI Immuno-Safety Career Symposium

Speaker Bios

Committee Publications

Filter

Nonclinical Safety Assessment of Engineered T Cell Therapies

Regulatory Toxicology and Pharmacology, 2021

Lebrec H, Maier CC, Maki K, Ponce R, Shenton J, & Green S

Over the last decade, immunotherapy has established itself as an important novel approach in the treatment of cancer, resulting in a growing importance in oncology. Engineered T cell therapies, namely chimeric antigen receptor (CAR) T cells and T cell receptor (TCR) T cell therapies, are platform technologies that have enabled ...

Read more

WP_Query Object
(
    [query] => Array
        (
            [post_type] => publication
            [posts_per_page] => 6
            [type] => 
            [area] => 
            [committee] => ITC
            [authors] => true
            [showtitle] => false
            [meta_query] => Array
                (
                    [relation] => AND
                )

            [tax_query] => Array
                (
                    [0] => Array
                        (
                            [taxonomy] => ilsi_committee
                            [field] => name
                            [terms] => ITC
                        )

                )

            [paged] => 1
            [meta_key] => _ilsi_date
            [orderby] => meta_value
            [order] => DESC
        )

    [query_vars] => Array
        (
            [post_type] => publication
            [posts_per_page] => 6
            [type] => 
            [area] => 
            [committee] => ITC
            [authors] => true
            [showtitle] => false
            [meta_query] => Array
                (
                    [relation] => AND
                )

            [tax_query] => Array
                (
                    [0] => Array
                        (
                            [taxonomy] => ilsi_committee
                            [field] => name
                            [terms] => ITC
                        )

                )

            [paged] => 1
            [meta_key] => _ilsi_date
            [orderby] => meta_value
            [order] => DESC
            [error] => 
            [m] => 
            [p] => 0
            [post_parent] => 
            [subpost] => 
            [subpost_id] => 
            [attachment] => 
            [attachment_id] => 0
            [name] => 
            [pagename] => 
            [page_id] => 0
            [second] => 
            [minute] => 
            [hour] => 
            [day] => 0
            [monthnum] => 0
            [year] => 0
            [w] => 0
            [category_name] => 
            [tag] => 
            [cat] => 
            [tag_id] => 
            [author] => 
            [author_name] => 
            [feed] => 
            [tb] => 
            [meta_value] => 
            [preview] => 
            [s] => 
            [sentence] => 
            [title] => 
            [fields] => all
            [menu_order] => 
            [embed] => 
            [category__in] => Array
                (
                )

            [category__not_in] => Array
                (
                )

            [category__and] => Array
                (
                )

            [post__in] => Array
                (
                )

            [post__not_in] => Array
                (
                )

            [post_name__in] => Array
                (
                )

            [tag__in] => Array
                (
                )

            [tag__not_in] => Array
                (
                )

            [tag__and] => Array
                (
                )

            [tag_slug__in] => Array
                (
                )

            [tag_slug__and] => Array
                (
                )

            [post_parent__in] => Array
                (
                )

            [post_parent__not_in] => Array
                (
                )

            [author__in] => Array
                (
                )

            [author__not_in] => Array
                (
                )

            [search_columns] => Array
                (
                )

            [ignore_sticky_posts] => 
            [suppress_filters] => 
            [cache_results] => 1
            [update_post_term_cache] => 1
            [update_menu_item_cache] => 
            [lazy_load_term_meta] => 1
            [update_post_meta_cache] => 1
            [nopaging] => 
            [comments_per_page] => 50
            [no_found_rows] => 
            [taxonomy] => ilsi_committee
            [term_id] => ITC
        )

    [tax_query] => WP_Tax_Query Object
        (
            [queries] => Array
                (
                    [0] => Array
                        (
                            [taxonomy] => ilsi_committee
                            [terms] => Array
                                (
                                    [0] => ITC
                                )

                            [field] => name
                            [operator] => IN
                            [include_children] => 1
                        )

                )

            [relation] => AND
            [table_aliases:protected] => Array
                (
                    [0] => wp_term_relationships
                )

            [queried_terms] => Array
                (
                    [ilsi_committee] => Array
                        (
                            [terms] => Array
                                (
                                    [0] => ITC
                                )

                            [field] => name
                        )

                )

            [primary_table] => wp_posts
            [primary_id_column] => ID
        )

    [meta_query] => WP_Meta_Query Object
        (
            [queries] => Array
                (
                    [0] => Array
                        (
                            [key] => _ilsi_date
                        )

                    [relation] => OR
                )

            [relation] => AND
            [meta_table] => wp_postmeta
            [meta_id_column] => post_id
            [primary_table] => wp_posts
            [primary_id_column] => ID
            [table_aliases:protected] => Array
                (
                    [0] => wp_postmeta
                )

            [clauses:protected] => Array
                (
                    [wp_postmeta] => Array
                        (
                            [key] => _ilsi_date
                            [compare] => =
                            [compare_key] => =
                            [alias] => wp_postmeta
                            [cast] => CHAR
                        )

                )

            [has_or_relation:protected] => 
        )

    [date_query] => 
    [request] => SELECT SQL_CALC_FOUND_ROWS  wp_posts.ID
					 FROM wp_posts  LEFT JOIN wp_term_relationships ON (wp_posts.ID = wp_term_relationships.object_id) INNER JOIN wp_postmeta ON ( wp_posts.ID = wp_postmeta.post_id )
					 WHERE 1=1  AND ( 
  wp_term_relationships.term_taxonomy_id IN (186)
) AND ( 
  wp_postmeta.meta_key = '_ilsi_date'
) AND ((wp_posts.post_type = 'publication' AND (wp_posts.post_status = 'publish' OR wp_posts.post_status = 'acf-disabled')))
					 GROUP BY wp_posts.ID
					 ORDER BY wp_postmeta.meta_value DESC
					 LIMIT 0, 6
    [posts] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 29712
                    [post_author] => 16
                    [post_date] => 2025-06-23 19:47:00
                    [post_date_gmt] => 2025-06-23 19:47:00
                    [post_content] => 
                    [post_title] => Regulatory T cell therapies to treat autoimmune diseases and transplant rejection
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => regulatory-t-cell-therapies-to-treat-autoimmune-diseases-and-transplant-rejection
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2025-06-23 19:48:18
                    [post_modified_gmt] => 2025-06-23 19:48:18
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://hesiglobal.org/?post_type=publication&p=29712
                    [menu_order] => 0
                    [post_type] => publication
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [1] => WP_Post Object
                (
                    [ID] => 29312
                    [post_author] => 16
                    [post_date] => 2025-03-03 20:11:51
                    [post_date_gmt] => 2025-03-03 20:11:51
                    [post_content] => 
                    [post_title] => Assessing the impact and risk of immunomodulatory compounds on pregnancy
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => assessing-the-impact-and-risk-of-immunomodulatory-compounds-on-pregnancy
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2025-03-03 20:11:51
                    [post_modified_gmt] => 2025-03-03 20:11:51
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://hesiglobal.org/?post_type=publication&p=29312
                    [menu_order] => 0
                    [post_type] => publication
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [2] => WP_Post Object
                (
                    [ID] => 28158
                    [post_author] => 16
                    [post_date] => 2024-06-11 13:39:46
                    [post_date_gmt] => 2024-06-11 13:39:46
                    [post_content] => 
                    [post_title] => Beyond MABEL: An Integrative Approach to First in Human Dose Selection of Immunomodulators by the Health and Environmental Sciences Institute (HESI) Immuno-Safety Technical Committee (ITC)
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => beyond-mabel-an-integrative-approach-to-first-in-human-dose-selection-of-immunomodulators-by-the-health-and-environmental-sciences-institute-hesi-immuno-safety-technical-committee-itc
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-06-11 13:39:46
                    [post_modified_gmt] => 2024-06-11 13:39:46
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://hesiglobal.org/?post_type=publication&p=28158
                    [menu_order] => 0
                    [post_type] => publication
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [3] => WP_Post Object
                (
                    [ID] => 28021
                    [post_author] => 16
                    [post_date] => 2024-04-29 18:27:04
                    [post_date_gmt] => 2024-04-29 18:27:04
                    [post_content] => 
                    [post_title] => Drug hypersensitivity reactions: review of the state of the science for prediction and diagnosis
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => drug-hypersensitivity-reactions-review-of-the-state-of-the-science-for-prediction-and-diagnosis
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-04-29 18:29:25
                    [post_modified_gmt] => 2024-04-29 18:29:25
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://hesiglobal.org/?post_type=publication&p=28021
                    [menu_order] => 0
                    [post_type] => publication
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [4] => WP_Post Object
                (
                    [ID] => 26519
                    [post_author] => 16
                    [post_date] => 2023-03-17 19:08:34
                    [post_date_gmt] => 2023-03-17 19:08:34
                    [post_content] => 
                    [post_title] => Current approaches to evaluate the function of cytotoxic T-cells in non-human primates
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => current-approaches-to-evaluate-the-function-of-cytotoxic-t-cells-in-non-human-primates
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-03-20 12:09:21
                    [post_modified_gmt] => 2023-03-20 12:09:21
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://hesiglobal.org/?post_type=publication&p=26519
                    [menu_order] => 0
                    [post_type] => publication
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [5] => WP_Post Object
                (
                    [ID] => 24259
                    [post_author] => 2
                    [post_date] => 2021-11-08 15:22:16
                    [post_date_gmt] => 2021-11-08 15:22:16
                    [post_content] => 
                    [post_title] => Nonclinical Safety Assessment of Engineered T Cell Therapies
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => nonclinical-safety-assessment-of-engineered-t-cell-therapies
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2022-02-17 14:16:23
                    [post_modified_gmt] => 2022-02-17 14:16:23
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://hesiglobal.org/?post_type=publication&p=24259
                    [menu_order] => 0
                    [post_type] => publication
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

        )

    [post_count] => 6
    [current_post] => -1
    [before_loop] => 
    [in_the_loop] => 
    [post] => WP_Post Object
        (
            [ID] => 29712
            [post_author] => 16
            [post_date] => 2025-06-23 19:47:00
            [post_date_gmt] => 2025-06-23 19:47:00
            [post_content] => 
            [post_title] => Regulatory T cell therapies to treat autoimmune diseases and transplant rejection
            [post_excerpt] => 
            [post_status] => publish
            [comment_status] => closed
            [ping_status] => closed
            [post_password] => 
            [post_name] => regulatory-t-cell-therapies-to-treat-autoimmune-diseases-and-transplant-rejection
            [to_ping] => 
            [pinged] => 
            [post_modified] => 2025-06-23 19:48:18
            [post_modified_gmt] => 2025-06-23 19:48:18
            [post_content_filtered] => 
            [post_parent] => 0
            [guid] => https://hesiglobal.org/?post_type=publication&p=29712
            [menu_order] => 0
            [post_type] => publication
            [post_mime_type] => 
            [comment_count] => 0
            [filter] => raw
        )

    [comment_count] => 0
    [current_comment] => -1
    [found_posts] => 64
    [max_num_pages] => 11
    [max_num_comment_pages] => 0
    [is_single] => 
    [is_preview] => 
    [is_page] => 
    [is_archive] => 1
    [is_date] => 
    [is_year] => 
    [is_month] => 
    [is_day] => 
    [is_time] => 
    [is_author] => 
    [is_category] => 
    [is_tag] => 
    [is_tax] => 1
    [is_search] => 
    [is_feed] => 
    [is_comment_feed] => 
    [is_trackback] => 
    [is_home] => 
    [is_privacy_policy] => 
    [is_404] => 
    [is_embed] => 
    [is_paged] => 
    [is_admin] => 
    [is_attachment] => 
    [is_singular] => 
    [is_robots] => 
    [is_favicon] => 
    [is_posts_page] => 
    [is_post_type_archive] => 
    [query_vars_hash:WP_Query:private] => 4815a457efa4edff51009f16a8babc51
    [query_vars_changed:WP_Query:private] => 
    [thumbnails_cached] => 
    [allow_query_attachment_by_filename:protected] => 
    [stopwords:WP_Query:private] => 
    [compat_fields:WP_Query:private] => Array
        (
            [0] => query_vars_hash
            [1] => query_vars_changed
        )

    [compat_methods:WP_Query:private] => Array
        (
            [0] => init_query_flags
            [1] => parse_tax_query
        )

    [query_cache_key:WP_Query:private] => wp_query:31a50b257621c7bbf26c3f0a0668c36a:0.11611400 17520534210.14463200 1752053421
)

Center for Translational Sciences

The Immuno-Safety Technical Committee (ITC)Ā is part of the Center for Translational Sciences. This HESI Center serves as a focal point for staff to share strategic approaches, scientific developments, management best practices and innovations with other related HESI committees.

Other Committees in the Center for Translational Sciences are:

For questions about the Center contact:

 

Contact Us

Health and Environmental Sciences Institute (HESI)

hesi@hesiglobal.org
Phone: +1-202-659-8404
Fax: +1-202-659-8403

740 15th Street NW, Suite 600
Washington, DC 20005

Stay Informed

Sign up for our monthly e-newsletter.